Press Releases
Madrid, Spain – October 30, 2025
Madrid, Spain – October 30, 2025 – Veos Pharmaceuticals S.L., a Spain-based biotechnology company pioneering natural innovations for health and sustainability, has won Third Prize at the 9th China (Shenzhen) International Innovation & Entrepreneurship Competition (IEIC) – Barcelona Division – and has been *selected to advance to the Industrial Phase in Shenzhen, China.
The recognition highlights ThymoTropin™, Veos Pharma’s breakthrough natural dual-action myostatin inhibitor and TRPV3 activator, a clinically validated, non-hormonal innovation that enhances muscle strength, endurance, and metabolic health. ThymoTropin™ addresses muscle loss associated with aging, GLP-1 treatments, and chronic disease — positioning Veos as a global leader in muscle health biotechnology.
“Being recognized among the top three companies and moving forward to the Shenzhen industrial phase represents a major milestone for Veos,” said Dr. Bassam Damaj, CEO and Co-Founder of Veos Pharmaceuticals. “It validates our vision of bringing scientifically proven, sustainable solutions from Spain to the global market — from health to agriculture and environmental biotechnology.”
The Shenzhen Industrial Phase will provide Veos with access to strategic investors, industrial partners, and Chinese market expansion opportunities, supporting the company’s plan to scale ThymoTropin™ and other Veos technologies across Asia.
Founded in 2022 and profitable since 2024, Veos Pharmaceuticals develops a portfolio of innovations spanning:
For more information, visit www.veospharma.com or contact:
Media Contact:
Veos Pharmaceuticals, S.L.
Email: info@veospharma.com
Tel: +34 911 925 649
Address: Calle Núñez de Balboa 35A, 28001
Madrid, Spain
Veos Pharmaceuticals Wins Third Prize at the 9th China (Shenzhen) International Innovation & Entrepreneurship Competition and Advances to Industrial Phase in Shenzhen
Madrid, Spain – October 30, 2025 – Veos Pharmaceuticals S.L., a Spain-based biotechnology company pioneering natural innovations for health and sustainability, has won Third Prize at the 9th China (Shenzhen) International Innovation & Entrepreneurship Competition (IEIC) – Barcelona Division – and has been *selected to advance to the Industrial Phase in Shenzhen, China.
The recognition highlights ThymoTropin™, Veos Pharma’s breakthrough natural dual-action myostatin inhibitor and TRPV3 activator, a clinically validated, non-hormonal innovation that enhances muscle strength, endurance, and metabolic health. ThymoTropin™ addresses muscle loss associated with aging, GLP-1 treatments, and chronic disease — positioning Veos as a global leader in muscle health biotechnology.
“Being recognized among the top three companies and moving forward to the Shenzhen industrial phase represents a major milestone for Veos,” said Dr. Bassam Damaj, CEO and Co-Founder of Veos Pharmaceuticals. “It validates our vision of bringing scientifically proven, sustainable solutions from Spain to the global market — from health to agriculture and environmental biotechnology.”
The Shenzhen Industrial Phase will provide Veos with access to strategic investors, industrial partners, and Chinese market expansion opportunities, supporting the company’s plan to scale ThymoTropin™ and other Veos technologies across Asia.
Founded in 2022 and profitable since 2024, Veos Pharmaceuticals develops a portfolio of innovations spanning:
- ThymoTropin™ – natural muscle health biotechnology
- VEOX-Preserve™ – food and beverage preservation
- OliQuell™ – water treatment and odor control
- BioPropello™ – sustainable agriculture and soil enhancement
- OleoSorb™ – oil absorption reduction technology
For more information, visit www.veospharma.com or contact:
Media Contact:
Veos Pharmaceuticals, S.L.
Email: info@veospharma.com
Tel: +34 911 925 649
Address: Calle Núñez de Balboa 35A, 28001
Madrid, Spain
